Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q1 2025 · 10-Q
Revenue$2.14M$2.14M+1,114.8% vs Q1 2024 Net Income-$6.67M-$6.67MN/M vs Q1 2024 EPS Diluted-$0.26-$0.26N/M vs Q1 2024 Gross Profit$1,325,000+2,844.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Operating Cash Flow-$5,839,000N/M Free Cash Flowderived-$6,146,000N/M Margins · derivedGross margin62.0%+36.4 pt vs Q1 2024
Operating margin-318.0%+4947.3 pt vs Q1 2024
Net margin-312.0%+4874.9 pt vs Q1 2024
ended Mar 31, 2025 · filed May 12, 2025 · 42 d after period end